BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Department of Bioengineering - ECPv5.14.0.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Department of Bioengineering
X-ORIGINAL-URL:https://be.iisc.ac.in
X-WR-CALDESC:Events for Department of Bioengineering
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20240205T160000
DTEND;TZID=UTC:20240205T170000
DTSTAMP:20260407T195947
CREATED:20240128T235733Z
LAST-MODIFIED:20240128T235733Z
UID:4394472-1707148800-1707152400@be.iisc.ac.in
SUMMARY:BE Seminar: Drug Delivery across Biological Barriers for combatting and preventing infectious diseases
DESCRIPTION:  \nTitle: Drug Delivery across Biological Barriers for combatting and preventing infectious diseases. \nProf. Dr. Claus-Michael Lehr \nHelmholtz Institute for Pharmaceutical Research Saarland (HIPS)\, Helmholtz Center for Infection Research (HZI) Dept of Drug Delivery. and \nSaarland University\, Dept of Pharmacy\, \nSaarbrücken\, Germany. \nAbstract: Urgently needed anti-infective drugs and vaccines must reach their targets safely and efficiently. Not only the body’s outer epithelia\, like e.g.\, gut\, skin and lung\, but also the bacterial cell envelope as well as the polymer matrix of bacterial biofilms represent important biological barriers which may delimit the transport of anti-infectives to their site of action (“bacterial bioavailability”). \nTo model the air-blood barrier of the peripheral human lung\, our group was the first who published a protocol for growing monolayers of human alveolar epithelial cells in primary culture (hAEpC) to develop functional tight junctions and high transepithelial electrical resistance (TEER). Later we introduced a first polyclonal human alveolar epithelial (hAELVi) and just recently a monoclonal cell line (Arlo) with similar properties. These epithelial cells may be implemented in various micro-physiological systems\, also to study the effect of breathing and co-cultivated with other cells types\, like e.g.\, macrophages or endothelial cells. A particular challenge is the mixed culture with bacterial biofilms to model chronic lung infections\, which can meanwhile be realized most elegantly by 3D bioprinting. \nSuch complex in-vitro models aim to reflect the (patho)physiology of specific organs or tissues either in healthy or reduce diseased state and to generate clinically meaningful readouts. They have been used for developing novel anti-infectives\, like e.g.\, quorum sensing inhibitors\, aiming to eradicate pathogens without inducing antimicrobial resistance. Aerosolizable nano-antibiotics are also being investigated to combat intracellular infections\, such as e.g.\, tuberculosis or viral infections by Crispr/CAS-like approaches. \nAbout The Speaker: Claus-Michael Lehr is Professor at Saarland University as well as cofounder and head of the department “Drug Delivery and Biological Barriers” at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)\, which was established as a branch of the Helmholtz Centre for Infection Research (HZI) Braunschweig in 2009. Prof. Lehr has also been cofounder of Across Barriers GmbH and of PharmBioTec GmbH\, a non-for-profit contract research organization. \nThe research theme of Professor Lehr’s team is (preferentially: non-invasive) drug delivery across biological barriers\, in particular the epithelia of the gastrointestinal tract\, the skin\, and the lungs. Recently\, this has been expanded to microbial barriers\, such as the bacterial cellular envelope\, biofilms and host cell membranes. A substantial part of the lab’s activities is dedicated to innovative carrier’s systems\, often based on nanotechnology\, capable of safely and efficiently delivering drugs and vaccines across these barriers. In this context\, the lab systematically investigates predictive cells and tissue models\, preferentially human-based\, to evaluate the safety and efficacy of novel therapeutic concepts and to facilitate their translation into the clinic.
URL:https://be.iisc.ac.in/event/be-seminar-drug-delivery-across-biological-barriers-for-combatting-and-preventing-infectious-diseases/
LOCATION:CES Seminar Hall\, CES Seminar Hall\, 3rd Floor\, Biological Science Building
CATEGORIES:Seminar
END:VEVENT
END:VCALENDAR